Author

Tan Wei

Senior Biostatistician, Roswell Park Cancer Institute - Cited by 2,263 - Biostatistics

Biography

Dr. Wei Tan is a Senior Biostatistician in the Department of Biostatistics and Bioinformatics in Roswell Park Cancer Institute. He published articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Photodynamic Therapy with 3-(1′-Hexyloxyethyl) Pyropheophorbide a for Cancer of the Oral Cavity
N Rigual, G Shafirstein, MT Cooper, H Baumann, DA Bellnier, U Sunar, ...Clinical Cancer Research 19 (23), 6605-6613, 2013201
81
2013
Low 25 (OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia
HJ Lee, JR Muindi, W Tan, Q Hu, D Wang, S Liu, GE Wilding, LA Ford, ...Cancer 120 (4), 521-529, 2014201
72
2014
All-arthroscopic anatomical reconstruction of anterior talofibular ligament using semitendinosus autografts
B Song, C Li, N Chen, Z Chen, Y Zhang, Y Zhou, W LiInternational orthopaedics 41, 975-982, 2017201
58
2017
Photodynamic therapy with 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a for early‐stage cancer of the larynx: Phase Ib study
G Shafirstein, NR Rigual, H Arshad, MT Cooper, DA Bellnier, G Wilding, ...Head & neck 38 (S1), E377-E383, 2016201
39
2016
Erlotinib and radiation therapy for elderly patients with esophageal cancer-clinical and correlative results from a prospective multicenter phase 2 trial
R Iyer, R Chhatrala, T Shefter, G Yang, U Malhotra, W Tan, C LeVea, ...Oncology 85 (1), 53-58, 2013201
36
2013
Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression
CE Nwogu, S Yendamuri, W Tan, E Kannisto, P Bogner, C Morrison, ...The Journal of Thoracic and Cardiovascular Surgery 145 (3), 702-708, 2013201
33
2013
Malignant adnexal tumors of the skin: a single institution experience
T Oyasiji, W Tan, J Kane, J Skitzki, V Francescutti, K Salerno, ...World Journal of Surgical Oncology 16, 1-7, 2018201
24
2018
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström Macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status
M Cea, A Cagnetta, C Acharya, P Acharya, YT Tai, C Yang, D Lovera, ...Clinical Cancer Research (24), 6099-6109, 2016201
22
2016
Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial
S Anwar, W Tan, J Yu, A Hutson, M Javle, R IyerJournal of gastrointestinal oncology 5 (6), 433, 2014201
21
2014
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy
AC Haller, W Tan, R Payne‐Ondracek, W Underwood, L Tian, C Morrison, ...The Prostate 74 (5), 509-519, 2014201
18
2014
Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer
M Mix, N Ramnath, J Gomez, C de Groot, S Rajan, S Dibaj, W Tan, ...World journal of clinical oncology 6 (5), 156, 2015201
18
2015
In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges
V Kasturirangan, BM Nair, MTS Kariapper, WG Lesniak, W Tan, ...Nanotoxicology 7 (4), 441-451, 2013201
17
2013
A phase Ib study of the FGFR/VEGFR inhibitor dovitinib with gemcitabine and capecitabine in advanced solid tumor and pancreatic cancer patients
WW Ma, H Xie, G Fetterly, L Pitzonka, A Whitworth, C LeVea, J Wilton, ...American journal of clinical oncology 42 (2), 184, 2019201
14
2019
Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non–small-cell lung cancer
GK Dy, PN Bogner, W Tan, TL Demmy, A Farooq, H Chen, SS Yendamuri, ...Journal of Thoracic Oncology 9 (2), 222-230, 2014201
13
2014
A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer
AK Singh, M Hennon, SJ Ma, TL Demmy, A Picone, EU Dexter, C Nwogu, ...BMC cancer 18 (1), 1-8, 2018201
13
2018
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first-or second-line agent
C Fountzilas, R Chhatrala, N Khushalani, W Tan, C LeVea, A Hutson, ...Cancer chemotherapy and pharmacology 80, 497-505, 2017201
12
2017
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
EA Griffiths, WE Brady, W Tan, CE Vigil, JE Thompson, LA Ford, ...Leukemia Research 43, 44-48, 2016201
11
2016
Quality-of-life (QOL) during screening for phase 1 trial studies in patients with advanced solid tumors and its impact on risk for serious adverse events
S Anwar, W Tan, CC Hong, S Admane, A Dozier, F Siedlecki, A Whitworth, ...Cancers 9 (7), 73, 2017201
8
2017
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age
CE Vigil, W Tan, G Deeb, SN Sait, AW Block, P Starostik, EA Griffiths, ...Leukemia research 37 (11), 146-1471, 2013201
8
2013
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia
ES Wang, A Zeidan, W Tan, GE Wilding, LA Ford, PK Wallace, TE Hahn, ...Leukemia & lymphoma 53 (10), 2085-2088, 2012201
7
2012

Referred From: https://scholar.google.co.in/citations?user=SKGPliEAAAAJ&hl=th

Cited by
Citations 2263
h-index 28
i10-index 47
Recommended Journals
Open Access Journals